Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors [clinicaltrials_resource:NCT00276159/outcome/1]
outcome [clinicaltrials_vocabulary:outcome]
Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors [clinicaltrials_resource:NCT00276159/outcome/1]
Bio2RDF identifier
NCT00276159/outcome/1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00276159/outcome/1
group [clinicaltrials_vocabulary:group]
measure [clinicaltrials_vocabulary:measure]
population [clinicaltrials_vocabulary:population]
Analysis not done to sale of agent - unable to perform.
Includes patients receiving at least 12 doses of 852A study drug.
Not able to analysis due to sale of agent - unable to perform.
safety issue [clinicaltrials_vocabulary:safety-issue]
time frame [clinicaltrials_vocabulary:time-frame]
Up to Week 12
type [clinicaltrials_vocabulary:type]
alternate
Number of Patients With 852A R ...... ation Criteria in Solid Tumors
@en
identifier
clinicaltrials_resource:NCT00276159/outcome/1
title
Stable disease in Non-Hogkin's ...... rophil count >500) at 4 weeks.
@en
type
label
Number of Patients With 852A R ...... esource:NCT00276159/outcome/1]
@en